



**Sleep duration as a risk factor for the development of type 2 diabetes or impaired glucose tolerance analyses of the Quebec family study**

Chaput, Jean-Philippe; Després, Jean-Pierre; Bouchard, Claude; Astrup, Arne; Tremblay, Angelo

*Published in:*  
Sleep Medicine

*DOI:*  
[10.1016/j.sleep.2008.09.016](https://doi.org/10.1016/j.sleep.2008.09.016)

*Publication date:*  
2009

*Document version*  
Early version, also known as pre-print

*Citation for published version (APA):*  
Chaput, J-P., Després, J-P., Bouchard, C., Astrup, A., & Tremblay, A. (2009). Sleep duration as a risk factor for the development of type 2 diabetes or impaired glucose tolerance: analyses of the Quebec family study. *Sleep Medicine*, 10(8), 919-924. <https://doi.org/10.1016/j.sleep.2008.09.016>

# **Sleep duration as a risk factor for the development of type 2 diabetes or impaired glucose tolerance: analyses of the Quebec Family Study**

**Short title: Sleep duration and type 2 diabetes**

Jean-Philippe Chaput, PhD<sup>1</sup>, Jean-Pierre Després, PhD<sup>2</sup>,  
Claude Bouchard, PhD<sup>3</sup>, Arne Astrup, MD, PhD<sup>4</sup> and Angelo Tremblay, PhD<sup>1,\*</sup>

<sup>1</sup>Division of Kinesiology, Department of Social and Preventive Medicine,  
Faculty of Medicine, Laval University, Quebec City, Quebec, Canada.

<sup>2</sup>Quebec Heart Institute, Hôpital Laval Research Center,  
Hôpital Laval, Quebec City, Quebec, Canada.

<sup>3</sup>Human Genomics Laboratory, Pennington Biomedical Research Center,  
Baton Rouge, Louisiana, USA.

<sup>4</sup>Department of Human Nutrition, Faculty of Life Sciences,  
University of Copenhagen, Copenhagen, Denmark.

\*Correspondence to:

Angelo Tremblay, PhD

Division of Kinesiology (PEPS), Department of Social and Preventive Medicine, Laval

University, Quebec City, Quebec, Canada, G1K 7P4. Phone: 418-656-7294. Fax: 418-656-3044.

E-mail: [angelo.tremblay@kin.msp.ulaval.ca](mailto:angelo.tremblay@kin.msp.ulaval.ca)

Word count: 3550 words and 3 tables

## **ABSTRACT**

**Objective:** To examine the long-term relationship between sleep duration and type 2 diabetes or impaired glucose tolerance (IGT).

**Methods:** Body composition measurements and self-reported sleep duration were determined in a longitudinal sample of 276 individuals aged 21 to 64 years followed for a mean of 6 years. Risk factors of type 2 diabetes/IGT over the follow-up were determined and relative risks (RRs) calculated for the development of type 2 diabetes/IGT by sleep duration group.

**Results:** Independent risk factors of type 2 diabetes/IGT over the follow-up included age, obesity, sleep duration, and glucose/insulin homeostasis indicators. Using adults with 7-8 h of sleep as a reference, the adjusted RR for the development of type 2 diabetes/IGT was 2.78 (1.61-4.12) for those with  $\leq 6$  h of sleep and 2.54 (1.42-3.53) for those with  $\geq 9$  h of sleep. These elevated RRs remained significant after adjustment for body mass index, waist circumference or percent body fat.

**Conclusion:** Short and long sleeping times are associated with a higher risk of developing type 2 diabetes/IGT, independent of several covariates. These results suggest that sleep duration may represent a novel risk factor for type 2 diabetes/IGT.

**Keywords:** glucose homeostasis; metabolism; prospective study; sleep loss; sleep time

## **INTRODUCTION**

By 2010, diabetes is predicted to affect 221 million people globally, which would represent an increase of 46% from the year 2000 [1]. The continued rise in type 2 diabetes ensures that this metabolic disorder will remain of public health significance for decades to come. Patients with this condition require frequent contact with the health care system for effective management and prevention of complications, are at increased risk of hospitalization for conditions such as cardiovascular and kidney disease, and have 10 year reduction in life expectancy. Although lifestyle changes such as improving diet composition, increasing physical activity, and losing weight are the cornerstones of diabetes prevention, efforts are needed to better understand other determinants of the disease and to develop additional prevention strategies. Understanding the link between diabetes and sleep may represent an important part of that effort.

Chronic partial sleep deprivation as a consequence of voluntary bedtime restriction is an endemic condition in modern society. In 1960, the American Cancer Society conducted a survey study in adults that showed modal sleep duration to be 8.0 to 8.9 h [2]. In 1995, a survey conducted by the National Sleep Foundation revealed that the mean sleep time had dropped to 7 h [3]. In 2004, more than 30% of adult men and women between the ages of 30 and 64 years reported sleeping less than 6 h per night [4]. Factors responsible for this situation include increases in environmental light, longer work days/longer commuting time, an increase in evening and night work, an increase in television use, and the advent of the personal computer and the Internet [5].

A rapidly growing body of laboratory [6-8] and epidemiological [9-11] evidence suggests that chronic partial sleep deprivation, a behavior that is specific to the human species and appears

to have become more prevalent during the past few decades, may increase the risk of type 2 diabetes. However, the underlying mechanisms of this presumed adverse influence of sleep deprivation on glucose metabolism is not well understood. Some data suggest that short-term partial sleep restriction could lead to insulin resistance by increasing sympathetic tone [12,13], raising evening cortisol concentrations [14], and decreasing cerebral glucose utilization [7,8]. These findings suggest that long-term sleep deprivation may predispose individuals to overt clinical diabetes. In a recent cross-sectional study, we have shown that short-duration sleepers had significantly lower glucose concentrations towards the end of an oral glucose challenge compared to average- and long-duration sleepers [15]. According to the glucostatic theory of appetite control [16], this represents a stimulus that can trigger episodes of hunger and spontaneous food intake, which may explain at least in part the greater risk of overweight displayed by short-duration sleepers, as shown in previous studies.

The present study examines longitudinal associations between sleep duration and type 2 diabetes or impaired glucose tolerance (IGT) in the Quebec Family Study (QFS). Furthermore, this study aims at examining glucose homeostasis in relation to sleep time, as an increase in energy intake and weight gain might be an unfortunate solution to restore glucose homeostasis in a context where insufficient sleep time becomes ingrained in the lifestyle of an individual. In this regard, we hypothesize that short sleep duration mediates its effects on diabetes through obesity.

## **METHODS**

### ***Subjects***

The QFS was initiated at Laval University in 1978. The primary objective of this study was to investigate the role of genetics in the etiology of obesity, fitness, and cardiovascular and

diabetes risk factors. In phase 1 of the study (1978 to 1981), a total of 1650 individuals from 375 families were recruited and measured. Recruitment was conducted irrespective of body weight during phase 1, which resulted in a cohort with a wide range of body mass index (BMI; in  $\text{kg/m}^2$ ), 13.8-64.9. In phases 2 (1989-1994) and 3 (1995 to 2001), 100 families from phase 1 were re-tested, and an additional 123 families with at least one parent and one offspring with a BMI of  $\geq 32$  were added to the cohort. Families were recruited through the media and were all French Canadians from the greater Quebec City area. This probability sample of the noninstitutionalized population of the greater Quebec City area comprised participants between the ages of 10 and 73 years. Because no oral glucose tolerance tests (OGTT) were performed in phase 1, the present analyses are from participants involved in phases 2 and 3. From the sample of 223 Caucasian nuclear families, 163 men and 199 women were potentially eligible for longitudinal analyses between phases 2 and 3. Additional details about the QFS have been previously published [17]. In the current study, baseline corresponded to phase 2 and the mean duration of follow-up between phases 2 and 3 was  $6.0 \pm 0.9$  years. The following exclusion criteria were applied: 1) age less than 21 years or greater than 64 years (27 men and 26 women excluded); 2) prevalent diabetes, defined as use of insulin or a hypoglycemic agent, a fasting plasma glucose level of 126 mg/dL or more ( $\geq 7.0$  mmol/L), or a 2 h postload plasma glucose level of 200 mg/dL or more ( $\geq 11.1$  mmol/L) or glucose intolerant, defined as a 2 h postload plasma glucose level of 140 mg/dL or more ( $\geq 7.8$  mmol/L) (8 men and 3 women excluded); and 3) body weight change greater than 2 kg during the 6 months prior to baseline testing (5 men and 7 women excluded). The age range of this study was chosen to fit a definition of adults being between the ages of 21 and 64, thus allowing a better generalization of the results obtained to this population. It is however relevant to mention that the results are not different with the inclusion of subjects under

21 and above 64 years of age. In addition, subjects with missing data on one or more of the variables investigated in one of the two testing sessions (baseline and 6 years later) were excluded (6 men and 4 women). The final longitudinal sample with full data included 276 individuals (117 men and 159 women). All subjects provided written informed consent to participate in the study. The project was approved by the Medical Ethics Committee of Laval University.

### ***Sleep duration assessment***

The number of hours of sleep was assessed at baseline and year 6 through a question inserted in a self-administered questionnaire on physical activity participation. The question formulation was: “On average, how many hours do you sleep a day?” We then classified the subjects into 3 sleep duration groups: short-duration sleepers ( $\leq 6$  hours of sleep; 21 men and 22 women), average-duration sleepers (7-8 hours of sleep; 85 men and 112 women) and long-duration sleepers ( $\geq 9$  hours of sleep; 11 men and 25 women). We decided to classify the subjects into 3 sleep duration groups in order to have sufficient sample size in each category and the choice of the 7-8 hours of sleep per night as the reference category eased interpretation of the relative risks (RRs) since subjects who reported getting 7-8 hours of sleep had the lowest incidence of diabetes. Furthermore, this is the largest group and 7.6 and 8 hours are the mean and median numbers of hours of sleep per night in this cohort, respectively. Since there was no gender interaction with the other factors, data for both sexes were combined.

### ***Anthropometric and body composition measurements***

Height was measured to the nearest 0.1 cm using a standard stadiometer, and body weight was measured to the nearest 0.1 kg using a digital panel indicator scale (Beckman Industrial Ltd,

Model 610/612, Scotland, UK). Body mass index (BMI) was calculated as body weight divided by height squared ( $\text{kg}/\text{m}^2$ ). Waist circumference was measured at the line between the lower border of the last rib and the upper border of the iliac crest. These anthropometric measurements were performed according to standardized procedures recommended at the Airlie Conference [18]. Furthermore, body density was obtained from the mean of six valid measurements derived from underwater weighing [19]. Before immersion in the hydrostatic tank, the helium dilution method of Meneely and Kaltreider [20] was used to determine the pulmonary residual volume. The percentage of total body fat was determined from body density with the equation of Siri [21]. Body fat mass was estimated from body weight and the percentage of body fat. These measurements were performed in the same way at both baseline and after 6 years.

### ***Oral glucose tolerance test (OGTT)***

A 75 g OGTT was performed in the morning after a 12 h overnight fast. Blood samples were collected in tubes containing EDTA and Trasylol (Miles Pharmaceuticals, Rexdale, ON, Canada) through a venous catheter from an antecubital vein at -15, 0, 15, 30, 45, 60, 90, 120, 150 and 180 min. Plasma glucose concentration was measured enzymatically [22], whereas plasma insulin concentration was determined by radioimmunoassay with polyethylene glycol separation [23]. Fasting insulin and glucose concentrations were calculated as the mean of the -15 and 0 min concentrations. The total glucose or insulin area under the curve (AUC) and the glucose area below fasting glucose concentration ( $G_{\text{ABF}}$ ) were calculated by the trapezoid method. We also calculated the homeostasis model assessment of insulin resistance (HOMA-IR) index [24].



### ***Assessment of the risk of type 2 diabetes/IGT***

Type 2 diabetes and IGT were defined in accordance with the American Diabetes Association and the World Health Organization criteria [25,26]. We defined type 2 diabetes as use of insulin or a hypoglycemic agent, a fasting plasma glucose level of 126 mg/dL or more ( $\geq 7.0$  mmol/L), or a 2 h postload plasma glucose level of 200 mg/dL or more ( $\geq 11.1$  mmol/L). On the other hand, IGT was defined as a 2 h postload plasma glucose level of 140 mg/dL or more ( $\geq 7.8$  mmol/L) in participants not meeting the criteria for type 2 diabetes.

### ***Potential covariates***

A broad set of potential covariates were measured via self-reported questionnaires at baseline and year 6. These include age, gender, study phase, length of follow-up, smoking habits [non or ex-smoker, light smoker ( $\leq 10$  cigarettes per day), heavy smoker ( $> 10$  cigarettes per day)], employment status (student, paid employment, looking for work, home duties, retired, disabled), educational level (high school, pre-university level [*CEGEP* for Quebec], university), annual household income (categorized into five groups ranging from  $< \$10,000$  to  $\$70,000$  or more), menopausal status (pre-menopausal, post-menopausal), shift-working history (none,  $< 5$  years,  $\geq 5$  years), resting metabolic rate (kcal/24 h using a ventilated hood and indirect calorimetry), physical activity level (min/day using a 3-day record), energy intake (kcal/day using a 3-day record), alcohol intake (g/day), and coffee intake (number of cups per day).

### ***Statistical analysis***

An unpaired Student's *t* test was used to compare baseline characteristics between men and women. Baseline covariates and glucose homeostasis indicators were compared between the

three sleep duration groups using an analysis of variance (continuous variables) and chi-squared test for comparison of frequencies (categorical variables). A Tukey's HSD post hoc test was performed to contrast mean differences between the sleep duration groups (continuous variables). Regression models were used to determine the association of these variables with the development of type 2 diabetes/IGT over the follow-up. In addition, multivariate logistic regression modeling was used to evaluate the relative risk for the development of type 2 diabetes/IGT by sleep duration group. We also controlled for BMI, % body fat and waist circumference (one at a time) in order to determine if the adjustment for any of these adiposity indices attenuated the association of sleep time with type 2 diabetes/IGT. The power calculation analysis revealed that 40 subjects in each sleep duration group are sufficient to detect a RR of 2.0 with an alpha of 0.05 and a power (1- $\beta$ ) of 80%. The power calculation is based on the assumption that there is an increase in the risk of developing type 2 diabetes/IGT for a short- and long-duration sleeper. Because some individuals in this family study are biologically related, we adjusted for clustering in the analyses to avoid underestimation of SD using the generalized estimating equations (GEE) statistical method. This procedure allowed us to model sleep duration and covariates as repeated measures at two time points (baseline and 6 years later). Data are given as means  $\pm$  SD unless otherwise noted. Statistical significance was set at a p value  $<0.05$ . All statistical analyses were performed using the JMP version 5.1.2 program (SAS Institute, Cary, NC, USA).

## **RESULTS**

Regarding baseline characteristics of men and women in the study, men had higher body weight, waist circumference and waist-to-hip ratios than women, whereas women had greater

percentage of body fat than men. However, age, BMI, body fat mass and total sleep duration were not significantly different between sexes. Table 1 presents baseline characteristics of subjects by sleep duration category. Short-duration sleepers presented higher body weight, BMI, percent body fat, abdominal circumference, fasting insulin level, HOMA-IR index and  $G_{ABF}$  as compared to average-duration sleepers. However, we were not able to detect any significant difference between the three sleeper groups for demographic characteristics, fasting glucose level, total glucose and insulin AUC, resting metabolic rate, and total caloric intake. Short-duration sleepers reported more vigorous physical activity participation than did average-duration sleepers.

Table 2 shows the factors that affect the risk of new diabetes or IGT during the 6-year follow-up period (unadjusted analysis). Age, short and long sleeping time, high adiposity indices, and elevated resting metabolic rate were associated with new cases of type 2 diabetes/IGT. Furthermore, glucose and insulin homeostasis indicators, annual family income, and shift-working history were predictors of type 2 diabetes/IGT over the follow-up period. In multiple regression models, only age, obesity, sleep duration and glucose/insulin homeostasis indicators were significantly and independently associated with new cases of type 2 diabetes/IGT. On the other hand, shift-working history, participation in vigorous physical activity, employment status, smoking habits, and coffee intake were independent predictors of sleep duration (data not tabulated).

Using adults with 7-8 h of sleep as the reference group, the adjusted RR for the development of type 2 diabetes/IGT was 2.78 (1.61-4.12) for the  $\leq 6$  h of sleep and 2.54 (1.42-3.53) for the  $\geq 9$  h of sleep groups (Table 3). After adjusting for waist circumference, those who slept 6 or fewer hours per day (RR = 2.42, 95% CI 1.49-3.33) and those who slept 9 or more hours (RR = 2.31, 95% CI 1.41-3.15) continued to be significantly more likely to have incident

diabetes/IGT. Consistent with our hypothesis that obesity would act as a partial mediator of the relationship between sleep duration and the incidence of diabetes/IGT, the addition of waist circumference, BMI or percent body fat further attenuated the results.

## **DISCUSSION**

The primary result of this study is that both short and long sleeping times are associated with a higher risk of developing type 2 diabetes/IGT. This finding is consistent with the majority of other studies investigating the association of sleep time with type 2 diabetes [10,11,27]. Furthermore, our results concur with a growing body of epidemiological evidence showing a U-shaped relationship between sleep duration and body weight [28,29], type 2 diabetes [11,27], coronary heart disease [30], and all-cause mortality [31]. Thus, a body of data suggests that there may be an “optimal sleeping time” of about 7-8 h per night in adults for the prevention of common diseases and premature death.

We are only beginning to recognize the hormonal and metabolic implications of variation in sleep duration. Physiological data suggest that short-term partial sleep restriction leads to striking alterations in metabolic and endocrine functions including decreased carbohydrate tolerance, insulin resistance, increased sympathetic tone, elevated cortisol concentrations, elevated levels of pro-inflammatory cytokines, and decreased leptin and increased ghrelin levels [7,28,32]. These findings suggest that long-term sleep curtailment may predispose individuals to abnormal metabolic regulation, including overt clinical diabetes. On the other hand, the mechanisms mediating the association of long sleep time with type 2 diabetes/IGT are more speculative. One plausible explanation is the sleep inducing and metabolic effects of pro-inflammatory cytokines which are elevated in the obese and in those with insulin resistance

[33,34]. Long sleep duration could also be reflective of sleep disorders such as sleep-disordered breathing which is associated with obesity, insulin resistance, and diabetes [35]. Seven days of extending the time spent in bed to 12 h per night was not associated with evidence of glucose intolerance [7]. Nurses' Health Study participants who reported sleeping 9 h or more per night reported 15% less physical activity per week than those sleeping 7-8 h per night [9]. This could result in a higher level of sedentariness which could over time favor impaired glucose regulation. However, the statistical adjustment for physical activity level in the present study has not provided support for this notion. One cannot exclude that some unmeasured variables may have confounded this association. In addition, we need to consider the possibility that self-reported long-duration sleepers are spending a lot of time in bed but not getting a lot of sleep, i.e. they might have poor sleep quality possibly due to sleep disorders or other health issues. Accordingly, the effects of prolonged sleep on biological mechanisms remain to be understood.

In the present study, adiposity was a risk factor for the development of type 2 diabetes/IGT in the multivariate adjusted model. Since obesity is a well-known risk factor for insulin resistance and type 2 diabetes, we hypothesized that the association between sleep duration and type 2 diabetes/IGT could be due to a confounding effect of adiposity or that sleeping time might mediate its effects on diabetes through weight gain. Consistent with our hypothesis, we observed that adjustment for adiposity attenuated the association of sleep time with type 2 diabetes/IGT, even though the association continued to be statistically significant. This finding is concordant with that of epidemiologic studies of sleep duration and diabetes risk [9-11,27]. Globally, these results suggest that the effects of sleep on subsequent onset of overt diagnosis of type 2 diabetes are not well understood. Additional studies using objective measures of sleep are required to determine if sleep curtailment and/or extension is truly part of the causal mechanisms leading to the development of diabetes.

Another aspect that deserves attention in this study is the fact that we did not find a gender difference in the risk of future diabetes by sleep duration. Mallon et al. [10] showed that the RR for the development of diabetes was significantly higher in men with short sleep duration (RR of 2.8) or difficulties maintaining sleep (RR of 4.8), after adjustment for age and other relevant risk factors, as compared to men reporting normal sleep patterns. Short or long sleep duration or sleep complaints did not, however, influence the risk of new diabetes in women in the same population-based study. On the other hand, the cross-sectional multicenter study from Tuomilehto et al. [36] reported a stronger association in women than in men, both for long and for short sleep duration, after controlling for obesity and other risk factors. The Nurses Health Study demonstrated an association between the amount of sleep and developing symptomatic diabetes in women [9]. Since the majority of studies have been conducted only in men, it is difficult to determine if there is indeed a gender effect.

Another issue pertains to glucose concentrations at the end of the OGTT, as we recently published results showing that short-duration sleepers presented lower glycemia at the end of an oral glucose challenge [15]. According to the glucostatic theory of appetite control [16], low glycemia is sufficient to trigger episodes of hunger and food intake. Thus, one could speculate that chronic lack of sleep stimulates appetite, promoting weight gain and impairing glycemic regulation, with a subsequently increased risk of IGT and eventually type 2 diabetes. Here again, the  $G_{ABF}$  was significantly higher in short-duration sleepers compared with average-duration sleepers and was a significant predictor of type 2 diabetes/IGT over the follow-up period. The addition of  $G_{ABF}$  in the multivariate logistic regression model (not shown) attenuated the RR for the incidence of type 2 diabetes/IGT in short-duration sleepers. Thus, this observation supports the hypothesis that  $G_{ABF}$  would act as a partial mediator of the relationship between sleep duration and type 2 diabetes/IGT.

Strengths of this study include its longitudinal design and use of objective measures of adiposity and glycemic status. Furthermore, data were obtained from both men and women and we used an approach that should serve to minimize confounding with repeated measures of sleep duration and covariates. However, the small sample size limits statistical power and generalizability of the results. Another limitation of the study was the use of self-reported sleep durations, as opposed to measured sleep durations. Although good agreement has been found in previous studies between self-reported sleep durations and those obtained through actigraphic monitoring [37,38], the validity of the single question method has not been fully determined. In addition, weekday and weekend sleep duration may differ significantly, with some individuals having a tendency to recapture sleep debt on the weekends. Finally, the possibility of a confounding effect in the relation of sleep time to type 2 diabetes/IGT from unmeasured variables such as sleep-disordered breathing, insomnia or depression, cannot be excluded.

In conclusion, data from this prospective cohort of adults suggest that sleep duration is a risk factor for the development of type 2 diabetes/IGT in both sexes. Both short and long sleep durations were associated with an increased incidence of type 2 diabetes/IGT, resulting in a U-shaped distribution of risk. This study lends empirical support to other published reports that indicate that the practice of good sleep hygiene is crucial and should be included with other behaviors to achieve good health.

## **ACKNOWLEDGEMENTS**

The authors express their gratitude to the subjects for their participation and the staff of the Physical Activity Sciences Laboratory at Laval University for their contribution to this study. We especially thank Dr. Germain Thériault, Guy Fournier, Monique Chagnon, Lucie Allard and Claude Leblanc for their help in the collection and analysis of the data.

## **SUPPORT**

The authors acknowledge the financial support over 20 years of the Medical Research Councils of Canada through several grants for the Quebec Family Study as well as other agencies from the governments of Quebec and Canada.

JPC is supported by a studentship from the Hôpital Laval Research Center. JPD is scientific director of the International Chair on Cardiometabolic Risk which is supported by an unrestricted grant awarded to Laval University by Sanofi-Avantis. CB is partially supported by the George A. Bray Chair in Nutrition. AT is partly funded by the Canada Research Chair in Environment and Energy Balance.



## REFERENCES

- [1] Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. *Diabet Med* 1997; 14 (Suppl 5): S1-S85.
- [2] Kripke D, Simons R, Garkinkel L, Hammond E. Short and long sleep and sleeping pills. Is increased mortality associated? *Arch Gen Psychiatry* 1979; 36: 103-116.
- [3] Gallup Organization. *Sleep in America*. Princeton, NJ, Gallup Organization, 1995.
- [4] National Center for Health Statistics. QuickStats: percentage of adults who reported an average of  $\leq 6$  h of sleep per 24-hour period, by sex and age group – United States, 1985 and 2004. *Morbidity and Mortality Weekly Report*, 2005.
- [5] Chokroverty S, editor. *Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects*. 2<sup>nd</sup> ed. Boston, MA: Butterworth and Heinemann, 1999; p. 14-16.
- [6] VanHelder T, Symons JD, Radomski MW. Effects of sleep deprivation and exercise on glucose tolerance. *Aviat Space Environ Med* 1993; 64: 487-492.
- [7] Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. *Lancet* 1999; 354: 1435-1439.
- [8] Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. *J Appl Physiol* 2005; 99: 2008-2019.
- [9] Ayas NT, White DP, Al-Delaimy WK *et al.* A prospective study of self-reported sleep duration and incident diabetes in women. *Diabetes Care* 2003; 26: 380-384.

- [10] Mallon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. *Diabetes Care* 2005; 28: 2762-2767.
- [11] Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. *Diabetes Care* 2006; 29: 657-661.
- [12] Irwin M, Thompson J, Miller C, Gillin JC, Ziegler M. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. *J Clin Endocrinol Metab* 1999; 84: 1979-1985.
- [13] Tochikubo O, Ikeda A, Miyajima E, Ishii M. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. *Hypertension* 1996; 27: 1318-1324.
- [14] Leproult R, Copinschi G, Buxton O, Van Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. *Sleep* 1997; 20: 865-870.
- [15] Chaput JP, Després JP, Bouchard C, Tremblay A. Association of sleep duration with type 2 diabetes and impaired glucose tolerance. *Diabetologia* 2007; 50: 2298-2304.
- [16] Mayer J. Glucostatic mechanism of regulation of food intake. *N Engl J Med* 1953; 249: 13-16.
- [17] Bouchard C. Genetic and body fat content. *Prog Obes Res* 1996; 5: 33-41.
- [18] The Airlie (VA) Consensus Conference. Standardization of anthropometric measurements. Champaign, IL: Human Kinetics Publishers, 1988.
- [19] Behnke AR, Wilmore JH. Evaluation and regulation of body build and composition. In: Behnke AR, editor. *Evaluation and Regulation of Body Build and Composition*. Englewood Cliffs, NJ: Prentice-Hall, 1974; p. 20-37.

- [20] Meneely GR, Kaltreider NL. Volume of the lung determined by helium dilution. *J Clin Invest* 1949; 28: 129-139.
- [21] Siri WE. The gross composition of the body. *Adv Biol Med Phys* 1956; 4: 239-280.
- [22] Richterich R, Dauwwalder H. Zur bestimmung der plasmaglukose-konzentration mit der hexokinase-glucose-6-phosphat-deshydrogenase-methode. *Schweiz Med Wochenschr* 1971; 101: 615-618.
- [23] Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. *J Clin Endocrinol Metab* 1971; 37: 732-738.
- [24] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412-419.
- [25] American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20: 1183-1197.
- [26] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15: 539-553.
- [27] Gangwisch JE, Heymsfield SB, Boden-Albala B *et al.* Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. *Sleep* 2007; 30: 1667-1673.
- [28] Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med* 2004; 1: 210-217.

- [29] Chaput JP, Després JP, Bouchard C, Tremblay A. The association between sleep duration and weight gain in adults: a 6-year prospective study from the Quebec Family Study. *Sleep* 2008; 31: 517-523.
- [30] Ayas NT, White DP, Manson JE *et al.* A prospective study of sleep duration and coronary heart disease in women. *Arch Intern Med* 2003; 163: 205-209.
- [31] Tamakoshi A, Ohno Y; JACC Study Group. Self-reported sleep duration as a predictor of all-cause mortality: results from the JACC study, Japan. *Sleep* 2004; 27: 51-54.
- [32] Vgontzas AN, Papanicolaou DA, Bixler EO *et al.* Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. *J Clin Endocrinol Metab* 2000; 85: 1151-1158.
- [33] Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. *Eur J Clin Invest* 2002; 32 (Suppl 3): 24-34.
- [34] Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. *J Am Soc Nephrol* 2004; 15: 2792-2800.
- [35] Resnick HE, Redline S, Shahar E *et al.* Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. *Diabetes Care* 2003; 26: 702-709.
- [36] Tuomilehto H, Peltonen M, Partinen M *et al.* Sleep duration is associated with an increased risk for the prevalence of type 2 diabetes in middle-aged women – the FIN-D2D survey. *Sleep Med* 2008; 9: 221-227.
- [37] Lockley SW, Skene DJ, Arendt J. Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. *J Sleep Res* 1999; 8: 175-183.
- [38] Hauri PJ, Wisbey J. Wrist actigraphy in insomnia. *Sleep* 1992; 15: 293-301.

**Table 1.** Baseline characteristics of subjects according to sleep duration group.<sup>1</sup>

<b>Variable</b>	<b>≤6 hours (n = 43)</b>	<b>7-8 hours (n = 197)</b>	<b>≥9 hours (n = 36)</b>
Age (years)	39.9 ± 14.9	38.9 ± 14.8	37.3 ± 18.2
Sex			
Male	21 (49)	85 (43)	11 (31)
Female	22 (51)	112 (57)	25 (69)
Body weight (kg)	76.9 ± 14.7*	69.3 ± 14.9	72.4 ± 23.3
BMI (kg/m <sup>2</sup> )	27.8 ± 5.5*	25.0 ± 4.7	26.1 ± 6.4
Body fat mass (kg)	22.6 ± 10.8*	17.8 ± 9.3	19.6 ± 11.1
Body fat (%)	28.5 ± 9.1*	25.2 ± 9.3	26.6 ± 9.3
Waist circumference (cm)	90.1 ± 15.0*	82.5 ± 14.0	83.8 ± 17.0
RMR (kcal/24 h)	1531 ± 295	1474 ± 253	1470 ± 311
Fasting glucose level (mmol/L)	5.10 ± 0.57	5.04 ± 0.50	4.89 ± 0.49
Fasting insulin level (pmol/L)	85.1 ± 71.1*	58.1 ± 45.7	79.2 ± 67.2
Total glucose AUC (mmol/L×min)	1151 ± 208	1135 ± 247	1202 ± 234
Total insulin AUC (pmol/L×min)	79862 ± 52620	68762 ± 61101	87623 ± 83271
HOMA-IR index	3.18 ± 2.45*	2.22 ± 1.92	2.94 ± 2.66
G <sub>ABF</sub> (mmol/L×min)	52.6 ± 16.4*	29.7 ± 18.7	39.1 ± 19.8
Smoking habits			
Non or ex-smoker	36 (83)	172 (87)	32 (89)
Light smoker <sup>2</sup>	2 (5)	12 (6)	3 (8)
Heavy smoker <sup>3</sup>	5 (12)	13 (7)	1 (3)
Employment status			
Student	7 (16)	43 (22)	7 (19)
Paid employment	25 (58)	116 (59)	18 (50)
Looking for work	2 (5)	5 (2)	2 (6)
Home duties	4 (9)	21 (11)	4 (11)
Retired	3 (7)	10 (5)	4 (11)
Disabled	2 (5)	2 (1)	1 (3)
Highest educational level			
High school	21 (49)	83 (42)	18 (50)
Pre-university level <sup>4</sup>	14 (32)	72 (37)	12 (33)
University	8 (19)	42 (21)	6 (17)
Total annual family income <sup>5</sup>			
\$70,000 or more	14 (32)	76 (38)	13 (36)
\$50,000-\$69,000	13 (30)	55 (28)	9 (25)
\$30,000-\$49,000	12 (28)	60 (30)	12 (33)
\$10,000-\$29,000	2 (5)	2 (1)	1 (3)
<\$10,000	2 (5)	4 (2)	1 (3)
Menopausal status			
In menopause	6 (14)	22 (11)	4 (11)
Not in menopause	37 (86)	175 (89)	32 (89)

Shift-working history			
None	35 (81)	166 (84)	28 (78)
<5 years	5 (12)	22 (11)	5 (14)
≥5 years	3 (7)	9 (5)	3 (8)
Alcohol intake (g/day)	7.58 ± 15.2	6.97 ± 13.3	7.55 ± 17.8
Coffee intake (cups/day)	3.00 ± 2.35	2.61 ± 2.11	2.51 ± 2.53
Energy intake (kcal/day)	2505 ± 676	2314 ± 713	2253 ± 570
Vigorous PA <sup>6</sup> (min/day)	14.7 ± 28.9	6.4 ± 9.8*	7.9 ± 11.3

---

BMI = body mass index; RMR = resting metabolic rate; AUC = area under the curve; HOMA-IR = homeostasis model assessment of insulin resistance; G<sub>ABF</sub> = glucose area below fasting glucose concentration; PA = physical activity.

\*Significantly different from the 7-8 hours sleeping group (p<0.05).

<sup>1</sup>Unless otherwise stated, values represent number, with percentage in parentheses.

<sup>2</sup>≤10 cigarettes per day.

<sup>3</sup>>10 cigarettes per day.

<sup>4</sup>In Quebec, it is a level of education of 2 years between high school (grade 11) and university (grade 13) termed *CEGEP (Collège d'Enseignement Général et Professionnel)*.

<sup>5</sup>Canadian dollars (CAD).

<sup>6</sup>Mean time spent in vigorous physical activity participation estimated as the number of periods graded 8 and 9 over the 3 days.

**Table 2.** Predictors of type 2 diabetes/IGT over the follow-up period.

Predicting variable	Type 2 diabetes/IGT		
	$\beta$	r	p
Age (years)	0.01	0.29	<0.01
Gender	-0.06	0.14	0.13
Study phase	0.01	0.04	0.54
Length of follow-up	0.02	0.04	0.56
Sleep duration (h)	-0.08	0.17	0.04
Body weight (kg)	0.01	0.36	<0.01
BMI (kg/m <sup>2</sup> )	0.03	0.33	<0.01
Body fat mass (kg)	0.02	0.41	<0.01
Body fat (%)	0.01	0.26	<0.01
Waist circumference (cm)	0.02	0.45	<0.01
RMR (kcal/24 h)	0.01	0.33	<0.01
Fasting glucose level (mmol/L)	0.98	0.62	<0.01
Fasting insulin level (pmol/L)	21.7	0.21	<0.01
Total glucose AUC (mmol/L×min)	0.01	0.53	<0.01
Total insulin AUC (pmol/L×min)	<0.01	0.23	<0.01
HOMA-IR index	0.09	0.38	<0.01
G <sub>ABF</sub> (mmol/L×min)	0.01	0.34	<0.01
Smoking habits	0.01	0.01	0.88
Employment status	-0.02	0.05	0.44
Educational level	-0.02	0.03	0.63
Total annual family income	-0.09	0.36	<0.01
Menopausal status	0.20	0.14	0.13
Shift-working history	0.02	0.17	0.04
Alcohol intake (g/day)	0.01	0.06	0.41
Coffee intake (cups/day)	0.01	0.04	0.55
Energy intake (kcal/day)	<0.01	0.12	0.10
Vigorous PA (min/day)	<0.01	0.01	0.74

BMI = body mass index; RMR = resting metabolic rate; AUC = area under the curve; HOMA-IR = homeostasis model assessment of insulin resistance; G<sub>ABF</sub> = glucose area below fasting glucose concentration; PA = physical activity.

**Table 3.** Relative risk for the incidence of type 2 diabetes or IGT by sleep duration group.

	Type 2 diabetes/IGT n	%	Multivariate adjusted <sup>a</sup>	Multivariate adjusted <sup>b</sup>
Sleeping time				
≤6 h	9	20.9	2.78 (1.61-4.12)	2.42 (1.49-3.33)
7-8 h	14	7.1	1.00	1.00
≥9 h	7	19.4	2.54 (1.42-3.53)	2.31 (1.41-3.15)

Data are RR (95% CI).

<sup>a</sup>Model adjusted for age, smoking habits, employment status, annual household income, shift-working history, resting metabolic rate, coffee intake, and participation in vigorous physical activity. These variables were chosen because they were either associated with sleep duration and/or type 2 diabetes/IGT over the follow-up.

<sup>b</sup>Model adjusted for the above-mentioned covariates plus waist circumference. Results were not materially different after controlling for BMI or percent body fat instead of waist circumference. Note: Covariates (including obesity covariates) were modeled as repeated measures at two time points (baseline and 6 years later), thus taking into account the evolution of both measures over time.